BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi Sells 2,320 Shares

BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of C$10.95, for a total transaction of C$25,404.00.

BioSyent Stock Performance

Shares of CVE RX traded up C$0.05 during trading hours on Monday, reaching C$11.05. The stock had a trading volume of 1,310 shares, compared to its average volume of 6,281. The firm has a 50-day moving average of C$10.34 and a 200-day moving average of C$9.49. The firm has a market cap of C$128.07 million, a price-to-earnings ratio of 18.33 and a beta of 0.93. BioSyent Inc. has a fifty-two week low of C$7.66 and a fifty-two week high of C$11.45. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19.

BioSyent (CVE:RX) last released its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$0.13. The firm had revenue of C$8.95 million for the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. Equities research analysts predict that BioSyent Inc. will post 0.6785935 earnings per share for the current year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.